Online citations, reference lists, and bibliographies.
← Back to Search

American Society Of Clinical Oncology Statement: Toward Individualized Care For Patients With Advanced Cancer.

J. Peppercorn, T. Smith, P. Helft, D. Debono, S. Berry, D. Wollins, D. M. Hayes, J. V. Von Roenn, L. Schnipper
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Patients with advanced incurable cancer face complex physical, psychological, social, and spiritual consequences of disease and its treatment. Care for these patients should include an individualized assessment of the patient's needs, goals, and preferences throughout the course of illness. Consideration of disease-directed therapy, symptom management, and attention to quality of life are important aspects of quality cancer care. However, emerging evidence suggests that, too often, realistic conversations about prognosis, the potential benefits and limitations of disease-directed therapy, and the potential role of palliative care, either in conjunction with or as an alternative to disease-directed therapy, occur late in the course of illness or not at all. This article addresses the American Society of Clinical Oncology's (ASCO's) vision for improved communication with and decision making for patients with advanced cancer. This statement advocates an individualized approach to discussing and providing disease-directed and supportive care options for patients with advanced cancer throughout the continuum of care. Building on ASCO's prior statements on end-of-life care (1998) and palliative care (2009), this article reviews the evidence for improved patient care in advanced cancer when patients' individual goals and preferences for care are discussed. It outlines the goals for individualized care, barriers that currently limit realization of this vision, and possible strategies to overcome these barriers that can improve care consistent with the goals of our patients and evidence-based medical practice.
This paper references
10.1002/ajh.21352
Update on the therapy for myelodysplastic syndrome
M. Kasner (2009)
10.1200/JCO.2003.09.124
Barriers to clinical trial participation by older women with breast cancer.
M. Kemeny (2003)
CF: Setting goals to maintain hope
JH VonRoenn (2003)
Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer
M. Dong (2006)
10.1200/JCO.2008.20.2408
Faculty development to change the paradigm of communication skills teaching in oncology.
A. Back (2009)
10.1097/CCO.0b013e328352ea20
Early palliative care for patients with metastatic cancer
J. Gaertner (2012)
10.1007/s00520-006-0027-8
Communication preferences and needs of cancer patients: the importance of content
A. Surbone (2006)
10.1007/s00520-007-0372-2
Patient–oncologist communication in advanced cancer: predictors of patient perception of prognosis
T. Robinson (2007)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.Coiffier B,et al.N Engl J Med 2002;346(4):235-42--CHOP+リツキシマブ併用療法は、CHOP療法を上回る治療法であり、DLBCLの治療動向に大きなimpactを与えた
謙 大間知 (2004)
10.1200/JCO.2003.10.161
Setting Goals to Maintain Hope
J. H. Roenn (2003)
10.1200/JCO.2002.08.004
Oncologists' attitudes toward and practices in giving bad news: an exploratory study.
W. Baile (2002)
10.1016/S0140-6736(09)60221-X
Multiple myeloma
M. Raab (2009)
10.1056/NEJMOA062867
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
B. Druker (2006)
10.1200/JCO.2009.26.3863
Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health.
A. Wright (2010)
10.1200/JCO.2009.23.1183
American Society of Clinical Oncology guidance statement: the cost of cancer care.
N. Meropol (2009)
10.1097/01.COT.0000370073.55788.2A
Study: Few Physicians Discussing End-of-Life Options with Advanced-Stage Patients
James M. Stubenrauch (2010)
10.1200/JCO.2008.19.9836
Metastatic renal cell carcinoma: many treatment options, one patient.
B. Rini (2009)
10.1089/jpm.2009.0089
A comprehensive case management program to improve palliative care.
C. Spettell (2009)
10.1200/JCO.2009.25.4672
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences.
J. Mack (2010)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1200/JCO.2007.12.4180
Oncologist communication about emotion during visits with patients with advanced cancer.
K. Pollak (2007)
10.1002/cncr.24761
Physician factors associated with discussions about end‐of‐life care
N. Keating (2010)
10.6004/JNCCN.2005.0024
Colon cancer. Clinical practice guidelines in oncology.
P. Engstrom (2003)
Health literacy, communication, and treatment decision-making in older cancer patients.
Sunil Amalraj (2009)
10.1093/ANNONC/MDM121
Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer.
F. Joly (2007)
10.1200/JCO.2007.15.8253
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?
C. Earle (2008)
10.6004/JNCCN.2010.0056
Non-small cell lung cancer clinical practice guidelines in oncology.
David S. Ettinger (2006)
10.1200/jco.1998.16.5.1986
Cancer care during the last phase of life.
D. S. Gordon (1998)
Colon cancer clinical practice guidelines
P. Engstrom (2005)
10.1001/archinternmed.2008.587
Health care costs in the last week of life: associations with end-of-life conversations.
B. Zhang (2009)
10.1056/NEJMOA011795
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
B. E. C. Oiffier (2002)
10.1056/NEJMoa1000678
Early palliative care for patients with metastatic non-small-cell lung cancer.
J. Temel (2010)
10.1097/PPO.0b013e3181f28ab3
Palliative Chemotherapy: When Is It Worth It and When Is It Not?
K. Swetz (2010)
10.1200/JCO.2008.20.1558
Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology.
F. Ferris (2009)
10.1200/JCO.2007.13.8156
Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?
C. Booth (2008)
Experts Debunk Health Care Reform Bill ’ s ‘ Death Panel ’ Rule
K Snow
10.1093/jnci/djp177
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
T. Fojo (2009)
10.1016/S1548-5315(11)70009-2
Providing palliative care and transitioning patients to hospice: how oncologists and palliative care specialists can work together
Sarah E. Harrington (2010)
10.6004/JNCCN.2009.0012
Breast cancer. Clinical practice guidelines in oncology.
R. Carlson (2009)
10.1200/jco.2003.10.161
Setting goals to maintain hope.
J. V. Von Roenn (2003)
Experts Debunk Health Care Reform Bill’s ‘Death Panel
K Snow (2009)
10.1200/JCO.2001.19.6.1728
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
P. Lara (2001)
10.1200/JCO.2008.18.1420
Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.
JEFFREYM. Peppercorn (2008)
10.1016/S0140-6736(02)07810-8
Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial
L. Fallowfield (2002)
10.1056/NEJMP068132
Access before approval--a right to take experimental drugs?
S. Okie (2006)
10.3816/CLC.2008.n.015
Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
R. Somer (2008)
10.1186/1471-2407-9-130
Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
J. Vardy (2008)
10.1158/1078-0432.CCR-10-1278
Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small
T. J. Smith (2010)



This paper is referenced by
Endpoints in advanced breast cancer: methodological aspects & clinical implications
E. D. Saad (2011)
10.1007/s12312-012-0832-6
Onkologische Palliativmedizin
Bernd Alt-Epping (2012)
10.3109/02688697.2011.651513
Patient selection and clinical outcomes in patients operated for brain metastases – is specialty of the referring physicians a prognostic factor?
A. Jakola (2012)
10.2512/JSPM.9.3_101
がん診療におけるQOLと生存期間の優先順位の検討─乳がん患者・医師・メディカルスタッフの比較
智子 谷山 (2014)
10.4103/ijccm.IJCCM_165_18
Definition of Terms Used in Limitation of Treatment and Providing Palliative Care at the End of Life: The Indian Council of Medical Research Commission Report
N. Salins (2018)
10.1093/annonc/mdu154
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
J. Grob (2014)
10.1016/j.ejca.2012.02.001
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
G. Scagliotti (2012)
10.1177/1049909118763796
Exploring Motivational Interviewing to Engage Latinos in Advance Care Planning: A Community-Based Social Work Intervention
F. Nedjat-Haiem (2018)
10.12968/ijpn.2014.20.12.600
Palliative care in Thailand.
Panit Krongyuth (2014)
10.1016/j.ctim.2018.04.012
On caring and sharing-Addressing psychological, biographical, and spiritual aspects in integrative cancer care: A qualitative interview study on physicians' perspectives.
G. Kienle (2018)
10.1159/000501129
Cancer Patients’ Preferences for either Quality of Life or a Longer Life Determine Their Willingness to Talk about Forgoing Cancer-Specific Treatment
K. Laryionava (2019)
10.2482/HAIGAN.52.995
Differences in End-of-life Care Continuing Chemotherapy to Near Death Between Lung Cancer Patients and Other Solid Tumor Patients
Kikuo Nakano (2012)
10.1200/JOP.2011.000469
Health care costs for patients with cancer at the end of life.
B. Chastek (2012)
10.1080/07347332.2013.822049
Exploring Dimensions of Coping in Advanced Colorectal Cancer: Implications for Patient-Centered Care
K. Sterba (2013)
10.1111/DDG.12113
Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms”
A. Pflugfelder (2013)
10.2217/BMT-2016-0023
Exploration of communication gaps among women with metastatic breast cancer, caregivers and oncologists
M. Citron (2016)
10.1016/j.jpainsymman.2019.01.016
The Stability of Treatment Preferences Among Patients With Advanced Cancer.
L. J. Jabbarian (2019)
10.1002/9781119341154.CH7
Principles of Palliative Radiation Therapy
Randy L. Wei (2017)
10.1016/j.jpainsymman.2015.03.016
Patient-Reported Outcomes for Determining Prognostic Groups in Veterans With Advanced Cancer.
V. Chang (2015)
10.1007/s00520-016-3211-5
What are the barriers faced by medical oncologists in initiating discussion of palliative care? A qualitative study in Flanders, Belgium
M. Horlait (2016)
10.1002/ijc.31957
Association between progression‐free survival and patients’ quality of life in cancer clinical trials
T. Hwang (2019)
10.1200/JGO.2016.007385
Chemotherapy Use at the End of Life in Uganda
D. Low (2017)
10.1177/1758834013500375
Early palliative care in cancer treatment: rationale, evidence and clinical implications
L. Howie (2013)
10.12816/0033790
Perspective of Lebanese oncologists on the symptom burden among adult cancer patients.
H. Rafei (2016)
10.1089/JPM.2016.0504
Implementing an Advance Care Planning Intervention in Community Settings with Older Latinos: A Feasibility Study
R. Nedjat-HaiemFrances (2017)
10.1016/j.pec.2018.08.016
Feasibility of a team based prognosis and treatment goal discussion (T-PAT) with women diagnosed with advanced breast cancer.
Mary M. Step (2019)
10.1007/978-3-319-16366-6
Improving Outcomes for Breast Cancer Survivors
P. A. Ganz (2015)
Editorial - Reflection on End-of-Life Care.
B. J. Brooks (2011)
10.1177/1049909118809975
Palliative Care Consultation Trends Among Hospitalized Patients With Advanced Cancer in the United States, 2005 to 2014
M. Rubens (2019)
10.1001/virtualmentor.2013.15.8.ecas3-1308
End-of-life decisions and off-label drug use.
L. Tenner (2013)
10.1136/bmj.j4530
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney S. Davis (2017)
10.1016/j.jpainsymman.2018.11.008
Factors Predisposing Terminally Ill Cancer Patients' Preferences for Distinct Patterns/States of Life-Sustaining Treatments Over Their Last Six Months.
Fur-Hsing Wen (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar